Reversal and Remission of T2DM – An Update for Practitioners
Lina Shibib,Mo Al-Qaisi,Ahmed Ahmed,Alexander D Miras,David Nott,Marc Pelling,Stephen E Greenwald,Nicola Guess
DOI: https://doi.org/10.2147/VHRM.S345810
2022-06-14
Vascular Health and Risk Management
Abstract:Lina Shibib, 1 Mo Al-Qaisi, 1 Ahmed Ahmed, 1 Alexander D Miras, 2 David Nott, 1 Marc Pelling, 1 Stephen E Greenwald, 3 Nicola Guess 4 1 Department of Surgery and Cancer, Imperial College London, London, UK; 2 Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; 3 Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK; 4 School of Life Sciences, Westminster University, London, UK Correspondence: Mo Al-Qaisi, Imperial Weight Centre, Imperial College Healthcare NHS Trust, Praed Street, London, W2 1NY, UK, Tel +44 7968 016315, Email Over the past 50 years, many countries around the world have faced an unchecked pandemic of obesity and type 2 diabetes (T2DM). As best practice treatment of T2DM has done very little to check its growth, the pandemic of diabesity now threatens to make health-care systems economically more difficult for governments and individuals to manage within their budgets. The conventional view has been that T2DM is irreversible and progressive. However, in 2016, the World Health Organization (WHO) global report on diabetes added for the first time a section on diabetes reversal and acknowledged that it could be achieved through a number of therapeutic approaches. Many studies indicate that diabetes reversal, and possibly even long-term remission, is achievable, belying the conventional view. However, T2DM reversal is not yet a standardized area of practice and some questions remain about long-term outcomes. Diabetes reversal through diet is not articulated or discussed as a first-line target (or even goal) of treatment by any internationally recognized guidelines, which are mostly silent on the topic beyond encouraging lifestyle interventions in general. This review paper examines all the sustainable, practical, and scalable approaches to T2DM reversal, highlighting the evidence base, and serves as an interim update for practitioners looking to fill the practical knowledge gap on this topic in conventional diabetes guidelines. Keywords: weight loss, very low energy, very low calorie, bariatric surgery, orlistat, electrical muscle stimulation, low carbohydrate, behaviour change, diabetes reversal, diabetes remission Type 2 diabetes mellitus (T2DM) is a complex, multifactorial, metabolic disease provoked by chronic overconsumption of unhealthy calories in those with a sedentary lifestyle and genetic predisposition, although no specific important risk gene(s) has been identified yet. It is preceded by a variable period of pre-diabetes during which time the body tries to compensate for blood glucose level spikes coinciding with increasing insulin resistance and attenuation of insulin production, but which ultimately progresses if the diet is left unchecked, resulting in a chronic state of elevated blood glucose level. Combined with increasingly sedentary lifestyles, T2DM is on course to be the largest non-communicable pandemic in human history. It has been estimated that the world prevalence of diabetes among adults (aged 20–79 years) in 2010 was 6.4%, affecting 285 million people, and this is projected to increase to 7.7%, or approximately 642 million adults, by 2030. 1 Although the prevalence of T2DM is higher in developed than in developing countries, 2,3 between 2010 and 2030, there is expected to be a 69% increase in the number of adults with diabetes in the developing world compared to a 20% increase in the West. 4 Since the advent of processed food in the 1950s, unhealthy constituents (refined sugars and saturated fats) have increasingly become the dominant part of total calorie intake in the developed world, whilst consumption of natural fibres from organic, fresh whole foods has fallen. The calorie-dense, widely available, and addictive menus touted to a poorly informed public have no doubt played a part in an obesity pandemic – facilitated by underlying epigenetic and genetic factors that are common. As Figure 1 reveals, the T2DM pandemic appears to be preceded by, and then moves in lockstep with, an underlying obesity pandemic. 5,6 Figure 1 BMI and risk of diabetes rise in lockstep. Note : Data from Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care . 1994;(9):961–969. 6 The annual cost of diabetes in the US has been estimated to have risen from US 327 billion in 2017 – that is a 33% increase, in just five years. 7 For the UK, the costs of diabetes to the National Health Service (NHS) have also risen, reaching a staggering US $ -Abstract Truncated-